Iradimed Corp. (IRMD) Tops Q2 EPS by 2c; Issues Confident Q3 Outlook, Boosts FY15 Guidance

Iradimed Corp. (NASDAQ: IRMD) reported Q2 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $7.6 million versus the consensus estimate of $7.1 million.

Iradimed Corp. sees Q3 2015 EPS of $0.16-$0.17, versus the consensus of $0.13. Iradimed Corp. sees Q3 2015 revenue of $7.7-7.8 million, versus the consensus of $7.4 million.

Iradimed Corp. sees FY2015 EPS of $0.63-$0.65, versus prior guidance of $0.57-$0.59 and the consensus of $0.50. Iradimed Corp. sees FY2015 revenue of $30.2-30.4 million, versus prior guidance of $29.0-30.0 million and the consensus of $29.4 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• NVE Corporation names new CEO and expands board to seven members
• Sun Communities names Ileana McAlary as general counsel and EVP